Product Sales

3 Months Ended

Mar. 31, 2023

Revenue from Contract with Customer [Abstract]

Product Sales

Product Sales

Net product sales consist of the following:

		Three Months Ended March 31,
(In millions)		2023		2022
EYLEA®	U.S.	$	1,433.8	$	1,517.6
Libtayo®(a)	U.S.	109.7		78.9
	ROW(b)	67.2		—
Praluent®	U.S.	40.2		33.6
Evkeeza®	U.S.	14.9		8.5
Inmazeb®	U.S.	2.2		—
		$	1,668.0	$	1,638.6
(a) Prior to July 1, 2022, Regeneron recorded net product sales of Libtayo in the United States and Sanofi recorded net product sales of Libtayo outside the United States. Effective July 1, 2022, the Company records global net product sales of Libtayo. See Note 3 for further details.
(b) Rest of world ("ROW")

As of March 31, 2023 and December 31, 2022, the Company had $3.578 billion and $3.586 billion, respectively, of trade accounts receivable that were recorded within Accounts receivable, net.

The Company had product sales to certain customers that accounted for more than 10% of total gross product revenue for the three months ended March 31, 2023 and 2022. Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:

	Three Months Ended March 31,
	2023		2022
Besse Medical, a subsidiary of AmerisourceBergen Corporation	52	%	55	%
McKesson Corporation	25	%	30	%